Skip to content
Dark
Search
Exclusive CEO Interviews
Home
Onyx Live
News
FDA Greenlit
Second Opinion
Exclusive Interviews
Press Releases
About Us
Read Onyx in other publications
Archive
March 2026
6:
Affinia cites low-dose engineered capsid strategy as AFTX-201 receives Fast Track
March 2026
5:
Twenty-seven years to one drug: How failure defined Cytokinetics before Aficamten
March 2026
4:
Slone Partners’ Leslie Loveless on the post-boom talent reset in biopharma
March 2026
4:
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 2026
4:
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
February 2026
27:
A national prostate screening programme would do more than detect cancer
February 2026
27:
FDA greenlights Ascendis’ once-weekly YUVIWEL to boost growth in children with achondroplasia
February 2026
25:
FDA proposes “plausible mechanism” route for individualized ultra-rare disease drugs
February 2026
24:
Immedica Pharma’s Loargys adds an enzyme-replacement entrant for ultra-rare ARG1-D–related hyperargininemia
February 2026
23:
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
February 2026
21:
FDA approves Vanda’s Bysanti for schizophrenia and bipolar I manic or mixed episodes
February 2026
20:
A world-expert in Stargardt disease has developed a pill to slow vision loss: why Tinlarebant could win FDA approval
February 2026
19:
Moderna-FDA public dispute cools as Administration agrees to review amended mRNA flu vaccine application
February 2026
18:
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
February 2026
18:
Verily launches free version of its Pre Exchange and Workbench solutions, powering precision health AI and discovery
February 2026
18:
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors
February 2026
18:
Belite Bio concludes phase 3 Stargardt trials with nearly 40% retinal cell preservation
February 2026
17:
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
February 2026
15:
How India is leading a cancer revolution
February 2026
13:
Verily Pre is Now “Awardable” in DoW’s Tradewinds Solutions Marketplace
February 2026
12:
Key risk statements from boxed warning on six menopausal HRT labels removed by FDA
February 2026
12:
Acrotech Biopharma brings a new topical PDE4 option - Adquey - into a crowded eczema market.
February 2026
12:
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
February 2026
12:
Guardant publishes Phase III data on ctDNA detection of residual disease after colon cancer surgery
February 2026
12:
FDA approves Novocure’s Optune Pax for locally advanced pancreatic cancer
February 2026
11:
Cellares secures $257 million Series D to scale automated cell therapy manufacturing
February 2026
11:
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 2026
9:
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
February 2026
9:
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
February 2026
6:
IND accepted: Affinia advances gene therapy for BAG3 DCM with FDA
February 2026
6:
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
February 2026
5:
ImmunityBio begins Phase 2 evaluation of chemotherapy-free NK-cell combination in indolent lymphomas
February 2026
5:
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
February 2026
5:
SpyGlass Pharma Announces Pricing of Initial Public Offering
February 2026
5:
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 2026
4:
Avidity details spin-off of precision cardiology assets as Novartis deal progresses
February 2026
4:
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 2026
4:
Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
February 2026
3:
MassBio Applauds Passage of Appropriations Bill, $400 Million Increase in NIH Funding
February 2026
3:
Guardant Health to Participate in Upcoming Investor Conferences
February 2026
3:
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
February 2026
3:
Piramal Pharma Solutions commercializes tablet-in-capsule drug delivery capability
February 2026
3:
NYSE listing and China licensing deal signal AstraZeneca’s two-market strategy
February 2026
3:
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 2026
3:
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 2026
3:
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 2026
2:
FDA approvals - January 2026
February 2026
2:
Avidity Biosciences Announces Expected Record Date for Spin-Off
February 2026
2:
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
February 2026
2:
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
February 2026
2:
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
February 2026
2:
Why Flatiron is betting on data quality, not hype, to power the next era of cancer care
January 2026
30:
“Efficacy with safety”: the north star behind Outpace’s next-gen engineered cell therapies
January 2026
29:
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
January 2026
29:
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
January 2026
29:
Lexicon Announces Proposed Public Offering of Common Stock
January 2026
29:
Opentrons Global Robotics Chief, James Atwood, Named Chief Executive Officer
January 2026
29:
From diagnostics to drug development: Scipher Medicine’s three-track strategy for high-impact immunology
January 2026
28:
Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation
January 2026
28:
nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B
January 2026
28:
Why Novellia thinks the best biopharma data strategy starts with patients, not pipelines
January 2026
27:
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
January 2026
27:
Mark Lappe’s lean biotech model: smaller teams, bigger wins
January 2026
26:
The lab-data marketplace powering precision medicine’s next wave
January 2026
23:
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
January 2026
23:
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
January 2026
23:
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
January 2026
23:
Biotech's new superstructure: Vivodyne's bid to turn human tissues into scalable, searchable data
January 2026
22:
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
January 2026
22:
Inside Fabian Gerlinghaus' Cellares and their $380M push to automate cell therapy manufacturing
January 2026
21:
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
January 2026
21:
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
January 2026
21:
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
January 2026
21:
Why Allucent says its global footprint is now a competitive edge in early-stage trials
January 2026
20:
Behind the Breakthrough: MassBio’s 2026 State of Possible Conference
January 2026
20:
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
January 2026
20:
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
January 2026
20:
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
January 2026
20:
Building for zero failure: How 4G Clinical is redefining trial supply management
January 2026
19:
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
January 2026
19:
How DNAnexus is enabling precision medicine from research to the point of care
January 2026
17:
How is AI changing biotech diligence? | Treehill Partners Ep. 1 | Onyx Live | JPM 2026
January 2026
16:
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
January 2026
16:
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
January 2026
16:
‘The moat is data’: Marc Tessier-Lavigne on building an AI-native drug company
January 2026
15:
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% Increase Year-Over-Year
January 2026
15:
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 2026
15:
The long game in cancer screening: Freenome’s data-first strategy
January 2026
15:
Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
January 2026
14:
Adrian Gottschalk, CEO, Foghorn Therapeutics | Onyx Live | JPM 2026
January 2026
14:
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
January 2026
14:
Daniel Green, CEO, eSpraye | JPM 2026
January 2026
14:
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
January 2026
14:
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
January 2026
14:
Why Trevi Therapeutics’ Jennifer Good believes treating cough means targeting the brain
January 2026
13:
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
January 2026
13:
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer
January 2026
13:
Nick Delmonico, CEO, Strados Labs | Onyx Live | JPM 2026
January 2026
13:
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
January 2026
13:
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
